Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 70 of 70 results for crohn's disease

  1. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  2. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

  3. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (HTG690)

    Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.

  4. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)

    We have moved Diagnostics guidance 22 to become HealthTech guidance 401. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  5. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  6. Intrapartum care (NG235)

    This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

  7. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

  8. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  9. NICE recommends treatment for people with short bowel syndrome

    A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above.